These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35765222)

  • 1. An expanded access protocol of RT001 in amyotrophic lateral sclerosis-Initial experience with a lipid peroxidation inhibitor.
    Yerton M; Winter A; Kostov A; Lieberman C; Gelevski D; Weber H; Doyle M; Kane G; Parikh N; Burke KM; Rohrer M; Stirrat T; Bruno M; Hochman A; Luppino S; Scalia J; Skoniecki D; D'Agostino D; Sinani E; Yu H; Sherman AV; Babu S; Berry JD; Midei MG; Milner PG; Cudkowicz ME; Paganoni S
    Muscle Nerve; 2022 Oct; 66(4):421-425. PubMed ID: 35765222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled phase 2 study to assess safety, tolerability, and efficacy of RT001 in patients with amyotrophic lateral sclerosis.
    Weemering DN; Midei M; Milner P; Gopalakrishnan V; Kumar A; Dannenberg AJ; Bunte TM; Foucher J; Ingre C; Ķēniņa V; Rallmann K; van den Berg LH; van Eijk RPA
    Eur J Neurol; 2023 Dec; 30(12):3722-3731. PubMed ID: 37550954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of infantile neuroaxonal dystrophy with RT001: A di-deuterated ethyl ester of linoleic acid: Report of two cases.
    Adams D; Midei M; Dastgir J; Flora C; Molinari RJ; Heerinckx F; Endemann S; Atwal P; Milner P; Shchepinov MS
    JIMD Rep; 2020 Jul; 54(1):54-60. PubMed ID: 32685351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia.
    Zesiewicz T; Heerinckx F; De Jager R; Omidvar O; Kilpatrick M; Shaw J; Shchepinov MS
    Mov Disord; 2018 Jul; 33(6):1000-1005. PubMed ID: 29624723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma and Red Blood Cell Membrane Accretion and Pharmacokinetics of RT001 (bis-Allylic 11,11-D2-Linoleic Acid Ethyl Ester) during Long Term Dosing in Patients.
    Brenna JT; James G; Midei M; Heerinckx F; Atwal P; Milner P; Schmidt K; van der Ploeg L; Fielding R; Shchepinov MS
    J Pharm Sci; 2020 Nov; 109(11):3496-3503. PubMed ID: 32871154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia.
    Lynch DR; Mathews KD; Perlman S; Zesiewicz T; Subramony S; Omidvar O; Vogel AP; Krtolica A; Litterman N; van der Ploeg L; Heerinckx F; Milner P; Midei M
    J Neurol; 2023 Mar; 270(3):1615-1623. PubMed ID: 36462055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded access protocol (EAP) program for access to investigational products for amyotrophic lateral sclerosis (ALS).
    Yerton M; Winter A; Gelevski D; Addy G; Kostov A; Lieberman C; Weber H; Doyle M; Kane G; Cohen C; Parikh N; Burke KM; Rohrer M; Stirrat T; Bruno M; Hochman A; Luppino S; Scalia J; D'Agostino D; Sinani E; Yu H; Drake K; Hagar J; Sherman AV; Babu S; Berry JD; Cudkowicz ME; Paganoni S
    Muscle Nerve; 2023 Jun; 67(6):456-463. PubMed ID: 36929648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease.
    Radunovic A; Annane D; Rafiq MK; Brassington R; Mustfa N
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD004427. PubMed ID: 28982219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and activity of anti-CD14 antibody IC14 (atibuclimab) in ALS: Experience with expanded access protocol.
    Gelevski D; Addy G; Rohrer M; Cohen C; Roderick A; Winter A; Carey J; Scalia J; Yerton M; Weber H; Doyle M; Parikh N; Kane G; Ellrodt A; Burke K; D'Agostino D; Sinani E; Yu H; Sherman A; Agosti J; Redlich G; Charmley P; Crowe D; Appleby M; Ziegelaar B; Hanus K; Li Z; Babu S; Nicholson K; Luppino S; Berry J; Baecher-Allan C; Paganoni S; Cudkowicz M
    Muscle Nerve; 2023 May; 67(5):354-362. PubMed ID: 36533976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter expanded access program for access to investigational products for amyotrophic lateral sclerosis.
    Neel DV; Baselga-Garriga C; Benson M; Keegan M; Chase M; D'Agostino D; Drake K; Hagar JL; Hasenoehrl MG; Kulesa-Kelley J; Leite A; Mohapatra S; Portaro SM; Pothier LM; Rosenthal J; Sherman AV; Yu H; McCaffrey A; Ho D; Luppino S; Bedlack R; Heitzman D; Ajroud-Driss S; Katz J; Felice K; Whitaker C; Ladha S; Alameda G; Locatelli E; Qureshi IA; Hotchkin MT; Hayden MR; Cudkowicz ME; Babu S; Berry JD; Paganoni S
    Muscle Nerve; 2024 Aug; 70(2):232-239. PubMed ID: 38842106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease.
    Radunovic A; Annane D; Rafiq MK; Mustfa N
    Cochrane Database Syst Rev; 2013 Mar; (3):CD004427. PubMed ID: 23543531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
    Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2002; (3):CD002064. PubMed ID: 12137643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease.
    Guo J; Zhou M; Yang M; Zhu C; He L
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008554. PubMed ID: 21901724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease.
    Fang J; Zhou M; Yang M; Zhu C; He L
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD008554. PubMed ID: 23728676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
    Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
    Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease.
    Baldinger R; Katzberg HD; Weber M
    Cochrane Database Syst Rev; 2012 Apr; (4):CD004157. PubMed ID: 22513921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALSUntangled No. 47: RT001.
    Bedlack R
    Amyotroph Lateral Scler Frontotemporal Degener; 2019 May; 20(3-4):294-297. PubMed ID: 30689428
    [No Abstract]   [Full Text] [Related]  

  • 19. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
    Pastula DM; Moore DH; Bedlack RS
    Cochrane Database Syst Rev; 2010 Jun; (6):CD005225. PubMed ID: 20556761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
    Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
    BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.